172 related articles for article (PubMed ID: 7967683)
21. Neutralization of heparin activity.
Pai M; Crowther MA
Handb Exp Pharmacol; 2012; (207):265-77. PubMed ID: 22566228
[TBL] [Abstract][Full Text] [Related]
22. Masking of heparin activity in the activated coagulation time (ACT) by platelet procoagulant activity.
Bode AP; Lust RM
Thromb Res; 1994 Mar; 73(5):285-300. PubMed ID: 7517074
[TBL] [Abstract][Full Text] [Related]
23. Absence of complement-mediated events after protamine reversal of heparin anticoagulation.
Wakefield TW; Kirsh MM; Till GO; Brothers TE; Hantler CB; Stanley JC
J Surg Res; 1991 Jul; 51(1):72-6. PubMed ID: 2067362
[TBL] [Abstract][Full Text] [Related]
24. Heparin Reversal After Cardiopulmonary Bypass: Are Point-of-Care Coagulation Tests Interchangeable?
Willems A; Savan V; Faraoni D; De Ville A; Rozen L; Demulder A; Van der Linden P
J Cardiothorac Vasc Anesth; 2016 Oct; 30(5):1184-9. PubMed ID: 27461795
[TBL] [Abstract][Full Text] [Related]
25. Restoration of the normal coagulation process: advances in therapies to antagonize heparin.
D'Ambra M
J Cardiovasc Pharmacol; 1996; 27 Suppl 1():S58-62. PubMed ID: 8938285
[TBL] [Abstract][Full Text] [Related]
26. Prolonged Activated Clotting Time after Protamine Administration Does Not Indicate Residual Heparinization after Cardiopulmonary Bypass in Pediatric Open Heart Surgery.
Yamamoto T; Wolf HG; Sinzobahamvya N; Asfour B; Hraska V; Schindler E
Thorac Cardiovasc Surg; 2015 Aug; 63(5):397-403. PubMed ID: 26121380
[TBL] [Abstract][Full Text] [Related]
27. Pilot validation of an individualised pharmacokinetic algorithm for protamine dosing after systemic heparinisation for cardiopulmonary bypass.
Miles LF; Marchiori P; Falter F
Perfusion; 2017 Sep; 32(6):481-488. PubMed ID: 28820026
[TBL] [Abstract][Full Text] [Related]
28. Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass.
Kikura M; Lee MK; Levy JH
Anesth Analg; 1996 Aug; 83(2):223-7. PubMed ID: 8694296
[TBL] [Abstract][Full Text] [Related]
29. Protamine reduces whole blood platelet aggregation after cardiopulmonary bypass.
Olsson A; Alfredsson J; Håkansson E; Svedjeholm R; Berglund J; Berg S
Scand Cardiovasc J; 2016; 50(1):58-63. PubMed ID: 26402229
[TBL] [Abstract][Full Text] [Related]
30. Analysis of the effect of varying protamine-to-heparin ratio on coagulation in vitro.
Ho LTS; McVey MJ; Kuiper GJAJM; Gross PL; Karkouti K
Br J Anaesth; 2021 Oct; 127(4):e128-e130. PubMed ID: 34334192
[No Abstract] [Full Text] [Related]
31. A novel protamine variant reversal of heparin anticoagulation in human blood in vitro.
Hulin MS; Wakefield TW; Andrews PC; Wrobleski SK; Stoneham MD; Doyle AR; Zelenock GB; Jacobs LA; Shanley CJ; TenCate VM; Stanley JC
J Vasc Surg; 1997 Dec; 26(6):1043-8. PubMed ID: 9423721
[TBL] [Abstract][Full Text] [Related]
32. Platelet factor four and protamine sulfate neutralization of heparin fractionated according to anionic charge density.
Poon MC; Hurst RE; Rives MS
Thromb Haemost; 1982 Apr; 47(2):162-5. PubMed ID: 7101237
[TBL] [Abstract][Full Text] [Related]
33. Validation of rotational thromboelastometry during cardiopulmonary bypass: A prospective, observational in-vivo study.
Gronchi F; Perret A; Ferrari E; Marcucci CM; Flèche J; Crosset M; Schoettker P; Marcucci C
Eur J Anaesthesiol; 2014 Feb; 31(2):68-75. PubMed ID: 23867776
[TBL] [Abstract][Full Text] [Related]
34. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
[TBL] [Abstract][Full Text] [Related]
35. Automated protamine dose assay in heparin reversal management after cardiopulmonary by pass.
Guarracino F; De Cosmo D; Penzo D; Tedesco M; Bossi A; Zussa C; Polesel E; De Stefani R
Minerva Anestesiol; 2001 Apr; 67(4):165-9. PubMed ID: 11376504
[TBL] [Abstract][Full Text] [Related]
36. Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery.
Najman DM; Walenga JM; Fareed J; Pifarré R
Ann Thorac Surg; 1993 Mar; 55(3):662-6. PubMed ID: 7680854
[TBL] [Abstract][Full Text] [Related]
37. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery.
Vonk AB; Veerhoek D; van den Brom CE; van Barneveld LJ; Boer C
J Cardiothorac Vasc Anesth; 2014 Apr; 28(2):235-41. PubMed ID: 24342152
[TBL] [Abstract][Full Text] [Related]
38. Complement activation by heparin-protamine complexes during cardiopulmonary bypass: effect of C4A null allele.
Shastri KA; Logue GL; Stern MP; Rehman S; Raza S
J Thorac Cardiovasc Surg; 1997 Sep; 114(3):482-8. PubMed ID: 9305203
[TBL] [Abstract][Full Text] [Related]
39. Use of the activated coagulation time in intraoperative heparin reversal for cardiopulmonary operations.
Mattox KL; Guinn GA; Rubio PA; Beall AC
Ann Thorac Surg; 1975 Jun; 19(6):634-8. PubMed ID: 1079715
[TBL] [Abstract][Full Text] [Related]
40. Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin.
Fareed J; Walenga JM; Pifarre R; Hoppensteadt D; Koza M
Haemostasis; 1991; 21 Suppl 1():64-72. PubMed ID: 1894198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
